DFTX — Definium Therapeutics, Inc.

DFTX closed at $35.68 (+0.03%) on Oct 26, 2026. Float: 132.2M shares. Latest SEC filing: 8-K on Sep 14, 2026.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Chart, dilution, float and news for DFTX in the TickerWise workspace.

Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Company profile

• Sector: Healthcare
• Industry: Medical - Pharmaceuticals
• Country: US
• Exchange: NASDAQ
• Employees: 74
• Website: https://definiumtx.com

Latest SEC filings for DFTX

• 2026-09-148-K
• 2026-09-088-K
• 2026-08-14SCHEDULE 13G/A
• 2026-08-128-K
• 2026-08-0610-Q
• 2026-08-068-K
• 2026-06-24424B5
• 2026-06-24424B5
• 2026-06-248-K
• 2026-06-228-K

Latest DFTX news

• 2026-09-28Definium Therapeutics Announces New Employee Inducement Grants Read article

Related companies

• ONC — BeOne Medicines Ltd.
• LQDA — Liquidia Corporation
• AVLN — Avalyn Pharma Inc. Common Stock
• LTGO — Latigo Biotherapeutics Inc.
• LFMDP — LifeMD, Inc.
• CGEM — Cullinan Therapeutics, Inc.
• CUVL — Clinuvel Pharmaceuticals Ltd.
• ETRA — Electra Therapeutics Inc.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Educational tool only — not investment advice.